Abstract:Significance: Reactive oxygen species (ROS) are generated during mitochondrial oxidative metabolism, and are tightly controlled through homeostatic mechanisms to maintain intracellular redox, regulating growth and proliferation in healthy cells. However, ROS production is perturbed in cancers where abnormal accumulation of ROS leads to oxidative stress and genomic instability, triggering oncogenic signaling pathways on one hand, while increasing oxidative damage and triggering ROS-dependent death signaling on the other. Recent Advances: Our review illuminates how critical interactions between ROS and oncogenic signaling, the tumor microenvironment, and DNA damage response (DDR) pathways have led to interest in ROS modulation as a means of enhancing existing anticancer strategies and developing new therapeutic opportunities. Critical Issues: ROS equilibrium exists via a delicate balance of pro-oxidant and antioxidant species within cells. "Antioxidant" approaches have been explored mainly in the form of chemoprevention, but there is insufficient evidence to advocate its routine application. More progress has been made via the "pro-oxidant" approach of targeting cancer vulnerabilities and inducing oxidative stress. Various therapeutic modalities have employed this approach, including direct ROS-inducing agents, chemotherapy, targeted therapies, DDR therapies, radiotherapy, and immunotherapy. Finally, emerging delivery systems such as "nanosensitizers" as radiotherapy enhancers are currently in development. Future Directions: While approaches designed to induce ROS have shown considerable promise in selectively targeting cancer cells and dealing with resistance to conventional therapies, most are still in early phases of development and challenges remain. Further research should endeavor to refine treatment strategies, optimize drug combinations, and identify predictive biomarkers of ROS-based cancer therapies.

The Endogenous Reactive Oxygen Species Promote NF-κB Activation by Targeting on Activation of NF-κB-inducing Kinase in Oral Squamous Carcinoma Cells

Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

Crosstalk of reactive oxygen species and NF-κB signaling

Insulin-like growth factor-I activates NFκB and NLRP3 inflammatory signalling via ROS in cancer cells

Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1–5 and Superoxide Dismutase 1–3 Signal Transduction Pathways

Endogenous and exogeneous stimuli-triggered reactive oxygen species evoke long-lived carbon monoxide to fight against lung cancer

Reactive Oxygen Species Bridge the Gap between Chronic Inflammation and Tumor Development

Inhibitors of NF-kappaB Reverse Cellular Invasion and Target Gene Upregulation in an Experimental Model of Aggressive Oral Squamous Cell Carcinoma.

Knockdown of NF-κB p65 Sensitizes Cellular Oxidative Damage in HCT116 Human Colonic Epithelial Cells

The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role

Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis.

Controlling Cancer Cells Using Reactive Oxygen Species

Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species

8-Oxoguanine DNA glycosylase 1 selectively modulates ROS-responsive NF-κB targets through recruitment of MSK1 and phosphorylation of RelA/p65 at Ser276

The Accomplices of NF-κB Lead to Radioresistance.

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements

Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword

Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment.

Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies

Redox Regulation of NOX Isoforms on FAK(Y397)/SRC(Y416) Phosphorylation Driven Epithelial-to-Mesenchymal Transition in Malignant Cervical Epithelial Cells

Modulation of redox signal transduction pathways in the treatment of cancer